Illumina's NovaSeq X Plus Boosts Genomic Research Capabilities in Europe
- Novogene Europe installed its fifth Illumina NovaSeq X Plus, enhancing high-throughput sequencing capabilities in Europe.
- The NovaSeq X Plus can generate 16 terabases of data in 48 hours, supporting rapid genomic analysis.
- Illumina's technology enables researchers to conduct ambitious studies with high accuracy and quick turnaround times.
Illumina's NovaSeq X Plus Strengthens Genomic Research in Europe
Novogene Europe enhances its genomic capabilities with the installation of its fifth Illumina NovaSeq X Plus sequencing system, marking a significant development in high-throughput sequencing in Europe. This strategic investment comes amid a growing demand for precise and rapid genomic analysis, reinforcing Novogene's stature as a leading partner in the genomics sector. According to Tingting Zhou, VP at Novogene Europe, the integration of the NovaSeq X Plus allows the company to meet client needs with unparalleled precision and speed, positioning them at the forefront of sequencing innovation. The advanced platform can generate an impressive 16 terabases of data in just 48 hours, making it a vital tool for researchers engaged in complex genomic studies such as whole-genome sequencing and single-cell RNA analysis.
The NovaSeq X Plus stands out as Illumina's most advanced sequencing technology, designed to support a wide array of applications that demand high accuracy and scale. This capability is crucial for researchers who are tackling intricate genomic questions and require quick turnaround times without compromising data quality. The additional system empowers Novogene’s customers to confidently embark on ambitious research projects, backed by a technology that not only delivers rapid results but also adheres to environmental responsibility standards. This commitment to sustainability aligns with the growing emphasis on responsible practices within the biotech industry.
The collaboration between Illumina and Novogene is long-standing, with both companies working synergistically to expand genomic capabilities across Europe. Bas Verhoef, SVP and Head of Region, Europe, at Illumina, emphasizes the significance of this partnership in enhancing service offerings to researchers. The NovaSeq X Plus is recognized for being the most rapidly adopted high-throughput sequencing platform, providing researchers with reliable, swift, and cost-effective next-generation sequencing services. Novogene Europe's systematic adoption of state-of-the-art technologies across its genomic, transcriptomic, microbial, and single-cell sequencing services further illustrates its commitment to localized support for European laboratories, ensuring that client needs are met with the highest standards of service.
In summary, the installation of the NovaSeq X Plus not only amplifies Novogene Europe's sequencing capacity but also signifies a crucial step in advancing genomic research in the region. This development reflects the ongoing evolution of high-throughput sequencing technologies and their integral role in supporting groundbreaking research in genomics. As demand for precision medicine continues to rise, investments like these are essential for ensuring that researchers have access to cutting-edge tools that can drive significant discoveries and innovations in the field.